Form D · Biotechnology
Graphite Bio, Inc.
South San Francisco, CA · CIK 0001815776
Offering snapshot reported Mar 19, 2021 · SEC filing
- Reported sold
- $151M Offering amount: $151M
- Investors reported
- 35 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 11, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 19, 2021 | Initial | $150,749,985 | No comparison | 35 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-392907
Source: Form D, filed Mar 19, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Abraham Bassan | Director |
| Jerel Davis | Director |
| Philip Gutry | Executive |
| Joe Jimenez | Director |
| Perry Karsen | Director |
| Josh Lehrer | Director, Executive |
| Matthew Porteus | Director |
| Carlo Rizzuto | Director |
| Maria Grazia Roncarolo | Director |
| Katherine Stultz | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
279 East Grand Avenue, Suite 430
South San Francisco, CA, 94080
South San Francisco, CA, 94080